The Institute for Clinical and Economic Review (ICER) on Feb. 22 announced plans to assess the comparative clinical effectiveness of Amarin Pharma’s icosapent ethyl and Janssen Pharmaceuticals’ rivaroxaban, two drugs used to treat additive cardiovascular disease (CVD).
According to a press release, ICER on its website has offered a timeline of posting dates and public comment periods for the assessment. An open input period opened Feb. 22, and will remain open until 5 p.m. EST March 12.
A draft scoping document on the assessment will be available March 18. There will be an open input period on that document for three weeks after its release.
To read the full press release on ICER’s website, click here.